Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma

J. Joshi, K. Jagannath, S. Chabbra, S. Rajan, J. Gogtay, C. J. Po, P. Mahadik, P. Deshpande (Mumbai, India)

Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Session: Combination therapy for asthma. Which, why and how?
Session type: Oral Presentation
Number: 2771
Disease area: Airway diseases

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Joshi, K. Jagannath, S. Chabbra, S. Rajan, J. Gogtay, C. J. Po, P. Mahadik, P. Deshpande (Mumbai, India). Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma. Eur Respir J 2005; 26: Suppl. 49, 2771

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting
Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Year: 2005


Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone
Source: Eur Respir J 2003; 21: 123-128
Year: 2003



Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma
Source: Eur Respir J 2007; 29: 871-878
Year: 2007



Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids
Source: Annual Congress 2006 - New features of paediatric asthma
Year: 2006


Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS)
Source: Eur Respir J 2003; 22: Suppl. 45, 312s
Year: 2003

Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005


Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 132s
Year: 2004

Is overall asthma control being achieved? A hypothesis-generating study
Source: Eur Respir J 2001; 17: 589-595
Year: 2001



Is the combination of long-acting β2-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001